Table 1.
Smoldering | Chronic | Lymphoma | Acute | |
---|---|---|---|---|
Anti-HTLV-I antibody | + | + | + | + |
Lymphocyte (×109/L) | <4 | ≥4 † | <4 | * |
Abnormal T lymphocytes | ≥5% | +‡ | ≤1% | +‡ |
Flower cells with T-cell marker | Occasionally | Occasionally | No | + |
LDH | ≤1.5 N | ≤2 N | * | * |
Corrected Ca2+ (mEq/L) | <5.5 | <5.5 | * | * |
Histology-proven lymphadenopathy | No | * | + | * |
Tumor lesion | ||||
Skin | § | * | * | * |
Lung | § | * | * | * |
Lymph node | No | * | Yes | * |
Liver | No | * | * | * |
Spleen | No | * | * | * |
Central nervous system | No | No | * | * |
Bone | No | No | * | * |
Ascites | No | No | * | * |
Pleural effusion | No | No | * | * |
Gastrointestinal tract | No | No | * | * |
HTLV-I, human T-lymphotropic virus type-I; LDH, lactate dehydrogenase; N, normal upper limit. * No essential qualification except terms required for other subtype(s); † Accompanied by T-lymphocytosis (3.5 × 109/L or more); ‡ In case abnormal T-lymphocytes are less than 5% in peripheral blood, histology-proven tumor lesion is required; § No essential qualification if other terms are fulfilled, but histology-proven malignant lesion(s) is required in case abnormal T-lymphocytes are less than 5% in peripheral blood.